Disc Medicine - Best comparison stock to Clinuvel, page-16

Disc up another 5.4% last night on impressive volume to a market cap of $2.5 Billion AUD. That is more than three times the valuation of CUV. CUV has the FDA, EMA drug and the absolute monopoly on EPP and great cash and profits with a Phase 3 into blockbuster Vitiligo. Loss making Disc just hoping to one day in many years to achieve approval in EPP and enter that market. I think it's fair to say shorters have had a big impact here at CUV as ASIC daily data shows and some effort needs to be made to protect shareholder interests right now via a share buyback. Disc is also so much better at attracting investor interest than at CUV and they need to lift their game a lot in that area - after all the newsletter stated it only took one institution buying a lot of shares in one month to take the CUV price over $40.

All IMO DYOR